150 mg dose also improved on time without troublesome dyskinesia
Written by Andrea Lobo | Oct. 13, 2026
- Solengepras (CVN424) is an investigational oral treatment being studied for motor and non-motor Parkinson’s symptoms.
- The Phase 3 ARISE trial found 150 mg significantly reduced average daily off time and improved daily motor function.
- Cerevance plans to discuss the results with the FDA and next steps for a potential New Drug Application.
The 150 mg dose of solengepras (CVN424), Cerevance’s investigational oral treatment for Parkinson’s disease, significantly reduced average daily off time — periods when symptoms reappear despite medication — compared with placebo, according to topline results from a Phase 3 trial.
The Phase 3 ARISE trial (NCT06553027) evaluated the safety and efficacy of solengepras in addition to standard treatments in people with Parkinson’s disease who experience motor fluctuations. The trial enrolled 341 participants at sites worldwide, completing enrollment earlier this year.
“ARISE met its primary endpoint and showed a consistent pattern of benefit across OFF time, ON time, daily motor function, daytime alertness and quality of life, together with favorable tolerability,” Craig Thompson, Cerevance’s CEO, said in a company press release. “We look forward to discussing these results with the FDA to determine next steps.”
How solengepras may help control Parkinson’s motor symptoms
Parkinson’s disease is caused by the loss of nerve cells that produce dopamine, a chemical messenger that helps control movement. Levodopa, which the brain converts into dopamine, is a standard treatment for easing Parkinson’s motor symptoms. However, long-term use of levodopa can lead to off periods and dyskinesia, or sudden, involuntary movements.
Solengepras is designed to block GPR6, a receptor found on specific nerve cells in the striatum, a brain region involved in controlling voluntary movement. By blocking GPR6, solengepras is designed to help restore balance between brain pathways involved in movement without directly altering dopamine levels or signaling.
The ARISE trial evaluated once-daily solengepras at 75 or 150 mg versus placebo in people with Parkinson’s who averaged at least three hours of off time per day despite treatment with levodopa and other Parkinson’s medications.
According to the company, the 150 mg dose met the trial’s primary goal, significantly reducing average daily off time by 0.61 hours, or about 37 minutes, versus placebo at Week 12. A difference between the treatment and placebo groups was seen as early as Week 2, the first assessment after treatment began, and at each subsequent visit through Week 12.
The 150 mg dose also increased on time without troublesome dyskinesia by 36 minutes versus placebo.
The 150 mg dose also significantly improved motor experiences of daily living, with a 1.91-point improvement versus placebo, as measured by Part 2 of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale. Participants receiving the 150 mg dose also had less daytime sleepiness on a secondary measure and better quality of life on an exploratory measure.
Recent Comments